<DOC>
	<DOCNO>NCT02367846</DOCNO>
	<brief_summary>This preclinical randomize crossover study examine effect oral versus non-oral contraceptive therapy bone turnover young exercise woman . In effort expose route-dependent effect oral versus non-oral contraceptive therapy bone turnover , investigator examine 1 ) effect ethinyl estradiol bone calcium balance use 41Ca technology 2 ) underlie physiological mechanism associate effect oral versus non-oral contraceptive therapy net bone calcium balance .</brief_summary>
	<brief_title>Assessing Impact Contraceptives Bone Health Using 41Ca</brief_title>
	<detailed_description>This study preclinical , multi-site study ( Penn State University Purdue University ) determine whether negative effect combine oral contraceptive ( COC ) therapy bone turnover dependent route administration attenuation effect observe comparable dose non-oral contraceptive therapy , vaginal contraceptive ( CVR ) therapy also test . Millions woman use COC therapy birth control purpose regulation menstrual cycle . CVR therapy relatively new FDA-approved contraceptive alternative COC . The purpose propose project investigate whether oral ethinyl estradiol ( EE ) may negatively impair bone turnover compare vaginally-administered EE young physically-active woman . A novel calcium tracer technology suitable rapidly assess change net bone calcium balance small sample size applied evaluate effect COC CVR therapy bone turnover . The radioisotope Calcium-41 ( 41Ca ) demonstrates increase sensitivity compare dual x-ray absorptiometry ( DXA ) increase specificity bone mineralization precision compare biochemical marker bone turnover . This study first study examine route estrogen administration affect bone turnover young physically active woman assess change net bone calcium balance different form contraceptive therapy . The overall purpose study explore effect oral versus vaginal contraceptive therapy bone turnover young exercise woman use 41Ca technology . In effort expose route-dependent effect oral versus non-oral contraceptive therapy bone turnover , investigator examine 1 ) effect ethinyl estradiol bone calcium balance use 41Ca technology 2 ) underlie physiological mechanism associate effect oral versus vaginal contraceptive therapy net bone calcium balance .</detailed_description>
	<mesh_term>Bone Diseases</mesh_term>
	<mesh_term>Bone Diseases , Developmental</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Contraceptives , Oral , Combined</mesh_term>
	<criteria>1 . Female 2 . Age 1825 yr 3 . BMI 1829 kg/m2 4 . Nonsmoking 5 . Willing refrain use hormonal contraceptive equilibration + baseline period study ( ~150 day ) 6 . Availability frequently visit laboratory next 12 month 7 . Not currently pregnant intend become pregnant next 12 month 8 . Not lactate 9 . No apparent metabolic , endocrine , musculoskeletal , severe psychiatric disease 10 . Willing maintain consistent exercise ( aerobic , weightbearing ) dietary habit preintervention intervention period 11 . Willing refrain supplement provide study staff next 12 month 12 . Variable physical activity acceptable , mode must primarily weight bear 13 . At least 9 menses past 12 month 1 . Nonweight bear exercise primary mode physical activity 2 . Resistance exercise training ( â‰¥ 2 time 30 minute per week resistance exercise ) 3 . Complete seasonal change impact mode physical activity 4 . Known suspected metabolic endocrine disease 5 . Smoking 6 . Pregnant 7 . Currently consume large amount soy product 8 . Current clinical eating disorder axis 1 psychiatric disorder bipolar disorder 9 . Oral hormonal contraceptive use last 6 month 10 . Hyperparathyroidism 11 . Liver renal disease 12 . Evidence malabsorption skeletal disorder 13 . Thyroid abnormality ( control hypothyroidism acceptable ) 14 . Chronic use nonsteroidal antiinflammatory drug ( NSAIDS ) 15 . Taking medication know interaction oral vaginal contraceptive therapy 16 . Other Exclusion Criteria propose World Health Organization COC Contraindications ( Grossman et al. , 2011 ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Calcium Tracer</keyword>
	<keyword>Oral Contraceptives</keyword>
	<keyword>Contraceptive Vaginal Ring</keyword>
	<keyword>Impact contraceptives bone health use 41Ca</keyword>
</DOC>